Trial Profile
A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary) ; Fludeoxyglucose F-18
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 23 Sep 2014 New trial record